AMHR2
Anti-Muellerian hormone type-2 receptor
Also known as: AMHR2_HUMAN, MISR2, MISRII
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q16671
- Gene
- AMHR2
- Ensembl
- ENSG00000135409
- Chromosome
- 12
- Canonical length
- 573 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Vesicles,Cytosol
OverviewNCBI Gene
This gene encodes the receptor for the anti-Mullerian hormone (AMH) which, in addition to testosterone, results in male sex differentiation. AMH and testosterone are produced in the testes by different cells and have different effects. Testosterone promotes the development of male genitalia while the binding of AMH to the encoded receptor prevents the development of the mullerian ducts into uterus and Fallopian tubes. Mutations in this gene are associated with persistent Mullerian duct syndrome type II. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Sep 2009]
Canonical amino-acid sequenceUniProt
573 residues, UniProt reviewed canonical sequence.
>Q16671|AMHR2
1 MLGSLGLWAL LPTAVEAPPN RRTCVFFEAP GVRGSTKTLG ELLDTGTELP RAIRCLYSRC
61 CFGIWNLTQD RAQVEMQGCR DSDEPGCESL HCDPSPRAHP SPGSTLFTCS CGTDFCNANY
121 SHLPPPGSPG TPGSQGPQAA PGESIWMALV LLGLFLLLLL LLGSIILALL QRKNYRVRGE
181 PVPEPRPDSG RDWSVELQEL PELCFSQVIR EGGHAVVWAG QLQGKLVAIK AFPPRSVAQF
241 QAERALYELP GLQHDHIVRF ITASRGGPGR LLSGPLLVLE LHPKGSLCHY LTQYTSDWGS
301 SLRMALSLAQ GLAFLHEERW QNGQYKPGIA HRDLSSQNVL IREDGSCAIG DLGLALVLPG
361 LTQPPAWTPT QPQGPAAIME AGTQRYMAPE LLDKTLDLQD WGMALRRADI YSLALLLWEI
421 LSRCPDLRPD SSPPPFQLAY EAELGNTPTS DELWALAVQE RRRPYIPSTW RCFATDPDGL
481 RELLEDCWDA DPEARLTAEC VQQRLAALAH PQESHPFPES CPRGCPPLCP EDCTSIPAPT
541 ILPCRPQRSA CHFSVQQGPC SRNPQPACTL SPVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AMHR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 39 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 39 nTPM
- ovary: 32 nTPM
- pancreas: 12 nTPM
- testis: 8.7 nTPM
- spleen: 5.4 nTPM
- skeletal muscle: 3.9 nTPM
Single-cell type
- granulosa cells: 143 nCPM
- adrenal cortex cells: 53 nCPM
- ovarian stromal cells: 27 nCPM
- sertoli cells: 25 nCPM
- mast cells: 21 nCPM
- megakaryocyte-erythroid progenitors: 9.7 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 1 nTPM
- midbrain: 0.5 nTPM
- pons: 0.1 nTPM
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AMHR2.
Disease | AllUniProt
Conditions AMHR2 is implicated in, by any mechanism.
- Persistent Muellerian duct syndrome 2 (PMDS2) MIM:261550
Disease | GeneticClinVar
40 pathogenic / likely-pathogenic of 175 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Persistent Mullerian duct syndrome
- Persistent mullerian duct syndrome, type II
- Genetic non-acquired premature ovarian failure
- Differences in sex development
- AMHR2-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.93
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.39
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- anti-Mullerian hormone receptor signaling pathway
- BMP signaling pathway
- cellular response to growth factor stimulus
- female gonad development
- male gonad development
- Mullerian duct regression
- sex differentiation
- transforming growth factor beta receptor signaling pathway
Molecular functions
- ATP binding
- hormone binding
- metal ion binding
- protein homodimerization activity
- transforming growth factor beta receptor activity
- transforming growth factor beta receptor activity, type II
- anti-Mullerian hormone receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Ser/Thr protein kinase, TGFB receptor
- Protein kinase domain
- Protein kinase-like domain superfamily
- Snake toxin-like superfamily
- Protein kinase domain
- Anti-muellerian hormone receptor, type II
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AMHR2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AMHR2 as an antibody target. Whether an autoantibody or antibody against AMHR2 could matter depends on whether native AMHR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AMHR2 is annotated at the cell surface, where native AMHR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label AMHR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...